Marimed (MRMD) Cash from Financing Activities (2014 - 2026)

Marimed (MRMD) has reported Cash from Financing Activities for 13 consecutive years, with -$1.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash from Financing Activities fell 50.37% year-over-year to -$1.2 million in Q2 2026; TTM through Jun 2026 was -$5.0 million, a 145.12% decrease from a year earlier, with the FY2025 full-year figure at -$4.7 million, down 257.89% from the prior year.
• Cash from Financing Activities was -$1.2 million for Q2 2026 at Marimed, down from -$1.1 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $23.3 million in Q1 2023 and troughed at -$3.1 million in Q3 2023.
• A 5-year average of $993722.2 and a median of -$849500.0 in 2024 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities sank 1349.15% in 2022 and soared 7176.6% in 2023, its largest moves.
• Over 5 years, Cash from Financing Activities stood at -$600000.0 in 2022, then surged by 850.0% to $4.5 million in 2023, then slumped by 119.84% to -$893000.0 in 2024, then dropped by 5.71% to -$944000.0 in 2025, then decreased by 28.39% to -$1.2 million in 2026.
• The last three Cash from Financing Activities figures came in at -$1.2 million (Q2 2026), -$1.1 million (Q1 2026), and -$944000.0 (Q4 2025), per Business Quant data.